Forian Inc. - Quarter Report: 2021 June (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarter ended June 30, 2021
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-40146
FORIAN INC.
(Exact name of registrant as specified in its charter)
Delaware
|
85-3467693
|
|
(State of Other Jurisdiction of incorporation or Organization)
|
(I.R.S. Employer Identification No.)
|
41 University Drive, Suite 400, Newtown, PA
|
18940
|
|
(Address of principal executive offices)
|
(Zip code)
|
Registrant’s telephone number, including area code: (267) 757-8707
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, $0.001 par value per share
|
FORA
|
The Nasdaq Stock Market LLC
|
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large
accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b 2 of the Exchange Act.
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b 2 of the Act). Yes ☐
No ☒
As of August 10, 2021, there were 32,558,617 shares outstanding of the
registrant’s common stock, including shares of unvested restricted stock.
PART I
|
FINANCIAL INFORMATION
|
|
Item 1.
|
3 |
|
3 |
||
4 |
||
5 |
||
8 |
||
9 |
||
Item 2.
|
30 |
|
Item 3.
|
41 |
|
Item 4.
|
41 |
|
PART II
|
OTHER INFORMATION
|
|
Item 1.
|
42 |
|
Item 1A.
|
43 |
|
Item 2.
|
43 |
|
Item 3.
|
44 |
|
Item 4.
|
44 |
|
Item 5.
|
44 |
|
Item 6.
|
44 |
|
45 |
FORIAN INC.
(formerly known as MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC)
AS OF JUNE 30, 2021 AND DECEMBER 31, 2020
June 30,
|
December 31,
|
|||||||
2021
|
2020
|
|||||||
Unaudited
|
||||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
4,763,324
|
$
|
665,463
|
||||
Marketable securities
|
12,505,118
|
11,501,844
|
||||||
Accounts receivable, net
|
1,390,277
|
22,996
|
||||||
Contract assets
|
582,597
|
196,701
|
||||||
Prepaid expenses
|
930,172
|
120,979
|
||||||
Other assets
|
450,000
|
—
|
||||||
Total current assets
|
20,621,488
|
12,507,983
|
||||||
Property and equipment, net
|
482,234
|
46,358
|
||||||
Intangible assets, net
|
10,163,914
|
—
|
||||||
Goodwill
|
8,700,912
|
—
|
||||||
Right of use assets, net |
988,674 | — | ||||||
Deposits and other assets
|
344,920
|
—
|
||||||
Total assets
|
$
|
41,302,142
|
$
|
12,554,341
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
1,977,152
|
647,601
|
||||||
Accrued expenses
|
2,346,567
|
480,741
|
||||||
Short-term operating lease liabilities |
264,329 | — | ||||||
Notes payable
|
18,054
|
—
|
||||||
Warrant liability
|
752,888
|
—
|
||||||
Deferred revenues
|
658,894
|
158,884
|
||||||
Total current liabilities
|
6,017,884
|
1,287,226
|
||||||
Long-term liabilities:
|
||||||||
Long-term operating lease liabilities
|
737,701
|
—
|
||||||
Total long-term liabilities
|
737,701
|
—
|
||||||
Total liabilities
|
6,755,585
|
1,287,226
|
||||||
Commitments and contingencies (Note 15)
|
|
|
||||||
Stockholders’ equity:
|
||||||||
Preferred Stock; par value $0.001;
5,000,000 Shares authorized; 0 issued and outstanding as of June 30, 2021 and December 31, 2020
|
—
|
—
|
||||||
Common Stock; par value $0.001; 95,000,000 Shares authorized; 31,198,721
issued and outstanding as of June 30, 2021 and 21,233,039 issued and outstanding as of December 31, 2020
|
31,199
|
21,233
|
||||||
Additional paid-in capital
|
52,264,976
|
17,514,907
|
||||||
Accumulated other comprehensive loss
|
145,250
|
—
|
||||||
Accumulated deficit
|
(17,894,868
|
)
|
(6,269,025
|
)
|
||||
Total stockholders’ equity
|
34,546,557
|
11,267,115
|
||||||
Total liabilities and stockholders’ equity
|
$
|
41,302,142
|
$
|
12,554,341
|
The accompanying notes are an integral part of these condensed consolidated financial statements
FORIAN INC.
(formerly known as MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC)
For the Three Months Ended
June 30,
|
For the Six Months Ended
June 30,
|
|||||||||||||||
2021
|
2020
|
2021 |
2020 |
|||||||||||||
Revenues:
|
||||||||||||||||
Information and Software
|
$
|
3,763,671
|
$
|
108,750
|
$ | 5,172,649 | $ | 175,417 | ||||||||
Services
|
492,336
|
—
|
588,647 | — | ||||||||||||
Other
|
291,978
|
—
|
407,298 | — | ||||||||||||
Total revenues
|
4,547,985
|
108,750
|
6,168,594 | 175,417 | ||||||||||||
Costs and Expenses:
|
||||||||||||||||
Cost of revenue
|
1,232,790
|
—
|
1,690,676 |
— |
||||||||||||
Research and development
|
1,949,926
|
426,398
|
3,447,764 | 815,391 | ||||||||||||
Sales and marketing
|
1,177,035
|
55,978
|
1,776,010 | 111,044 | ||||||||||||
General and administrative
|
6,577,696
|
326,832
|
9,362,258 | 629,085 | ||||||||||||
Depreciation and amortization
|
595,488
|
1,419
|
783,072 | 1,873 | ||||||||||||
Transaction related expenses
|
—
|
90,506
|
1,210,279 | 90,506 | ||||||||||||
Total costs and expenses
|
11,532,935
|
901,133
|
18,270,059 | 1,647,899 | ||||||||||||
Loss From Operations
|
(6,984,950
|
)
|
(792,383
|
)
|
(12,101,465 | ) | (1,472,482 | ) | ||||||||
Other Income (Expense):
|
||||||||||||||||
Change in fair value of warrant liability
|
(128,800
|
)
|
—
|
494,827 | — | |||||||||||
Interest and investment income, net
|
(20,446
|
)
|
744
|
(19,205 | ) | 5,707 | ||||||||||
Total other income, net
|
(149,246
|
)
|
744
|
475,622 | 5,707 | |||||||||||
Net loss before income taxes
|
(7,134,196
|
)
|
(791,639
|
)
|
(11,625,843 | ) | (1,466,775 | ) | ||||||||
Income tax expense
|
—
|
—
|
— | — | ||||||||||||
Net Loss
|
$
|
(7,134,196
|
)
|
$
|
(791,639
|
)
|
$ | (11,625,843 | ) | $ | (1,466,775 | ) | ||||
Other comprehensive loss:
|
||||||||||||||||
Changes in foreign currency translation adjustment
|
169,256
|
—
|
145,250 | — | ||||||||||||
Total other comprehensive loss
|
$
|
169,256
|
$
|
—
|
$ | 145,250 | $ | — | ||||||||
Total comprehensive loss
|
$
|
(6,964,940
|
)
|
$
|
(791,639
|
)
|
$ | (11,480,593 | ) | $ | (1,466,775 | ) | ||||
Basic and diluted net loss per common share
|
$
|
(0.23
|
)
|
$
|
(0.06
|
)
|
$ | (0.42 | ) | $ | (0.13 | ) | ||||
Weighted-average shares outstanding:
|
30,996,735
|
13,797,652
|
27,534,359 | 11,066,456 |
The accompanying notes are an integral part of these condensed consolidated financial statements
FORIAN INC.
(formerly known as MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC)
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020
Preferred Stock
|
Common Stock
|
||||||||||||||||||||||||||||
|
Shares |
Par Value
@$0.001
per share
|
Shares
|
Par Value
@$0.001
per share
|
Additional
Paid In
Capital
|
Accumulated
Other
Comprehensive
Loss
|
Accumulated
Deficit
|
Stockholders’
Equity
|
|||||||||||||||||||||
Balance at January 1, 2021
|
$
|
—
|
21,233,039
|
$
|
21,233
|
$
|
17,514,907
|
$ |
—
|
$
|
(6,269,025)
|
|
$
|
11,267,115
|
|||||||||||||||
Issuance of Forian Common stock in Helix Acquisition
|
8,408,383
|
8,408
|
18,446,376
|
—
|
—
|
18,454,784
|
|||||||||||||||||||||||
Forian Restricted Stock Vesting from MOR unvested restricted stock
|
343,123
|
343
|
5,102
|
—
|
—
|
5,445
|
|||||||||||||||||||||||
Issuance of common stock warrants
|
—
|
—
|
389,976
|
—
|
—
|
389,976
|
|||||||||||||||||||||||
Forian shares issued upon exercise of MOR Class B options
|
10,167
|
10
|
292,820
|
—
|
—
|
292,830
|
|||||||||||||||||||||||
Stock based compensation expense
|
—
|
—
|
3,612,728
|
—
|
—
|
3,612,728
|
|||||||||||||||||||||||
Issuance of Forian common stock
|
1,191,743
|
1,192
|
11,967,460
|
—
|
—
|
11,968,652
|
|||||||||||||||||||||||
Issuance of Forian common stock upon exercise of stock options
|
12,266
|
13
|
35,607
|
—
|
—
|
35,620
|
|||||||||||||||||||||||
Foreign currency translation
|
—
|
—
|
—
|
145,250
|
—
|
145,250
|
|||||||||||||||||||||||
Net loss
|
(11,625,843) |
(11,625,843) |
|||||||||||||||||||||||||||
Balance at June 30, 2021
|
— |
$
|
—
|
31,198,721
|
$
|
31,199
|
$
|
52,264,976
|
$
|
145,250
|
$
|
(17,894,868)
|
|
$
|
34,546,557
|
The accompanying notes are an integral part of these condensed consolidated financial statements
FORIAN INC.
(formerly known as MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020
Preferred Stock
|
Common Stock
|
||||||||||||||||||||||||||||
|
Shares |
Par Value
@$0.001
per share
|
Shares
|
Par Value
@$0.001
per share
|
Additional
Paid
In Capital
|
Accumulated
Other
Comprehensive
Income
|
Accumulated
Deficit
|
Stockholders’
Equity
(Deficit)
|
|||||||||||||||||||||
Balance at January 1, 2020
|
$
|
—
|
7,713,528
|
$
|
7,713
|
$
|
1,000,098
|
$ |
—
|
$
|
(1,288,842
|
)
|
$
|
(281,031
|
)
|
||||||||||||||
Issuance of MOR Series S Units in March 2020
|
5,316,284
|
5,316
|
3,310,384
|
3,315,700
|
|||||||||||||||||||||||||
Conversion of Promissory Notes for MOR Series S Units in March 2020
|
295,501
|
296
|
184,004
|
184,300
|
|||||||||||||||||||||||||
Vested MOR Class B Profit Interest Units
|
741,677
|
742
|
11,028
|
11,770
|
|||||||||||||||||||||||||
Net loss
|
$
|
(1,466,775
|
)
|
(1,466,775
|
)
|
||||||||||||||||||||||||
Balance at June 30, 2020
|
—
|
$
|
—
|
14,066,990
|
$
|
14,067
|
$
|
4,505,514
|
$
|
—
|
$
|
(2,755,617
|
)
|
$
|
1,763,964
|
Preferred Stock
|
Common Stock
|
||||||||||||||||||||||||||||
|
Shares |
Par Value
@$0.001
per share
|
Shares
|
Par Value
@$0.001
per share
|
Additional
Paid
In Capital
|
Accumulated
Other
Comprehensive
Loss
|
Accumulated
Deficit
|
Stockholders’
Equity
|
|||||||||||||||||||||
Balance at April 1, 2021
|
$
|
—
|
29,824,424
|
$
|
29,824
|
$
|
37,510,532
|
$ |
(24,006
|
)
|
$
|
(10,760,672
|
)
|
$
|
26,755,678
|
||||||||||||||
Forian Restricted Stock Vesting from MOR unvested restricted stock
|
170,288
|
170
|
2,532
|
2,702
|
|||||||||||||||||||||||||
Issuance of Forian common stock
|
1,191,743
|
1,192
|
11,967,460
|
11,968,652
|
|||||||||||||||||||||||||
Stock based compensation expense
|
2,748,845
|
2,748,845
|
|||||||||||||||||||||||||||
Issuance of Forian common stock upon exercise of stock options
|
12,266
|
13
|
35,607
|
35,620
|
|||||||||||||||||||||||||
Foreign currency translation
|
169,256
|
169,256
|
|||||||||||||||||||||||||||
Net loss
|
(7,134,196
|
)
|
(7,134,196
|
)
|
|||||||||||||||||||||||||
Balance at June 30, 2021
|
—
|
$
|
—
|
31,198,721
|
$
|
31,199
|
$
|
52,264,976
|
$
|
145,250
|
$
|
(17,894,868
|
)
|
$
|
34,546,557
|
The accompanying notes are an integral part of these condensed consolidated financial statements
FORIAN INC.
(formerly known as MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020
Preferred Stock
|
Common Stock
|
||||||||||||||||||||||||||||
|
Shares |
Par Value
@$0.001
per share
|
Shares
|
Par Value
@$0.001
per share
|
Additional
Paid
In Capital
|
Accumulated
Other
Comprehensive
Income
|
Accumulated
Deficit
|
Stockholders’
Equity
|
|||||||||||||||||||||
Balance at April 1, 2020
|
$
|
—
|
13,654,750
|
$
|
13,655
|
$
|
4,499,384
|
$ |
—
|
$
|
(1,963,978
|
)
|
$
|
2,549,061
|
|||||||||||||||
Vested MOR Class B Profit Interest Units
|
412,240
|
412
|
6,130
|
6,542
|
|||||||||||||||||||||||||
Net loss
|
|
(791,639
|
)
|
(791,639
|
)
|
||||||||||||||||||||||||
Balance at June 30, 2020
|
—
|
$
|
—
|
14,066,990
|
$
|
14,067
|
$
|
4,505,514
|
$
|
—
|
$
|
(2,755,617
|
)
|
$
|
1,763,964
|
The accompanying notes are an integral part of these condensed consolidated financial statements
FORIAN INC.
(Formerly known as MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC)
(UNAUDITED)
For the Six Months Ended June 30,
|
||||||||
2021
|
2020
|
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
Net loss
|
$
|
(11,625,843
|
)
|
$
|
(1,466,775
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
783,072
|
1,873
|
||||||
Amortization on right of use asset
|
94,010 |
— |
||||||
Realized and unrealized gain on marketable securities
|
(2,331
|
)
|
(5,621
|
)
|
||||
Provision for doubtful accounts
|
50,813
|
—
|
||||||
Stock-based compensation expense
|
3,618,173
|
11,770
|
||||||
Change in fair value of warrant liability
|
(494,827
|
)
|
—
|
|||||
Non-cash transaction expenses
|
389,976
|
—
|
||||||
Change in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(931,715
|
)
|
(200,000
|
)
|
||||
Contract assets
|
(108,808
|
)
|
—
|
|||||
Prepaid expenses
|
(589,859
|
)
|
(387,845
|
)
|
||||
Changes in lease liabilities during the period |
(105,378) | ) | — |
|||||
Deposits and other assets
|
(344,338
|
)
|
—
|
|||||
Accounts payable
|
(1,105,422
|
)
|
268,876
|
|||||
Accrued expenses |
1,944,639 |
— |
||||||
Deferred revenues
|
179,074
|
259,583
|
||||||
Other long-term liabilities
|
—
|
—
|
||||||
Net cash used in operating activities
|
(8,248,764
|
)
|
(1,518,139
|
)
|
||||
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
Additions to property and equipment
|
(328,303
|
)
|
(13,937
|
)
|
||||
Purchase of marketable securities
|
(12,504,788
|
)
|
(2,888,648
|
)
|
||||
Sale of marketable securities
|
11,503,845
|
1,757,701
|
||||||
Cash acquired as part of business combination
|
1,310,977
|
—
|
||||||
Net cash used in investing activities
|
(18,269
|
)
|
(1,144,884
|
)
|
||||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
Proceeds from issuance of MOR Series S units
|
—
|
3,315,700
|
||||||
Proceeds from exercise of MOR Class B options
|
292,830
|
—
|
||||||
Payments on notes payable and financing arrangements
|
(2,747
|
)
|
—
|
|||||
Proceeds from exercise of common
stock options
|
35,620 | — | ||||||
Proceeds from sale of common stock
|
11,968,652 | — | ||||||
Net cash provided by financing activities
|
12,294,355
|
3,315,700
|
||||||
Effect of foreign exchange rate changes on cash
|
70,539
|
—
|
||||||
Net change in cash
|
4,097,861
|
652,677
|
||||||
Cash and cash equivalents, beginning of period
|
665,463
|
494
|
||||||
Cash and cash equivalents, end of period
|
$
|
4,763,324
|
$
|
653,171
|
||||
Supplemental disclosure of cash flow information:
|
||||||||
Cash paid for interest
|
$
|
724
|
$
|
—
|
||||
Cash paid for taxes |
$ | — | $ | — | ||||
Non-cash Investing and Financing Activities: |
||||||||
Conversion of promissory notes to Series S units
|
$
|
—
|
$
|
184,300
|
||||
Non-cash consideration for Helix acquisition
|
$
|
18,454,784
|
$
|
—
|
The accompanying notes are an integral part of these condensed consolidated financial statements
FORIAN INC.
(Formerly known as MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC)
Note 1
|
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS
|
Forian Inc. (the “Company” or “Forian”) was incorporated in Delaware on October 15, 2020 as a wholly owned subsidiary of Medical Outcomes Research Analytics, LLC
(“MOR”) for the purpose of effecting the Business Combination (as defined below). All activity of the Company through March 2, 2021 relates only to MOR. MOR was established on May 6, 2019 in Delaware. MOR Analytics, LLC and COR Analytics, LLC
are wholly owned subsidiaries of MOR. The Company provides innovative software solutions, proprietary data and predictive analytics to optimize the operational, clinical and financial performance of its customers within the healthcare and
cannabis industries. The Company’s mission is to provide its customers with the best-in-class critical technology services through a single integrated platform that enables its customers to operate their businesses more safely, efficiently and
profitably and to serve its customers and its customers’ stakeholders and constituencies more comprehensively. The Company represents the unique convergence of proprietary healthcare and consumer data, innovative data management capabilities
and intelligent data science with a leading cannabis technology platform yielding the combined power to drive innovation and transparency across the industries it serves.
On March 2, 2021 (the “Merger Closing Date”), pursuant to the Agreement and Plan of Merger, dated as of October 16, 2020, as amended by Amendment to Agreement and
Plan of Merger, dated as of December 30, 2020, as further amended by Amendment No. 2 to Agreement and Plan of Merger, dated February 9, 2021 (together, the “Merger Agreement”), by and among Helix Technologies, Inc. (“Helix”), the Company and
DNA Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), Merger Sub merged with and into Helix, with Helix being the surviving corporation as a wholly owned subsidiary of the Company (the “Merger”). Each share of Helix
common stock was exchanged for 0.05 shares of Company common stock in the Merger. Helix provides traceability and point of sale
technology, analytics solutions and other products to customers within each vertical of the cannabis industry to help them improve the performance of their business.
Immediately prior to the Merger Closing Date, pursuant to the Equity Interest Contribution Agreement, dated March 2, 2021 (the “Contribution Agreement”), by and
among the Company, MOR and each equity holder of MOR, such equity holders contributed their interests in MOR to the Company in exchange for shares of Company common stock (the “Contribution” and, together with the Merger, the “Business
Combination”). Upon the closing of the Contribution, MOR became a wholly owned subsidiary of the Company. Each unit of MOR was exchanged for 1.7776
shares of Company common stock in the Merger, subject to adjustments pursuant to the Contribution Agreement.
Pursuant to the Merger Agreement, while the Company is the legal acquirer, the Merger was accounted for as a reverse acquisition using the acquisition method of
accounting in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”). As such, MOR is deemed to be the accounting acquirer for financial reporting
purposes.
Note 2
|
BASIS OF PRESENTATION
|
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (“U.S. GAAP”). Certain footnotes and other financial information normally required by U.S. GAAP have been condensed or omitted in accordance with instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of
management, such statements include all adjustments which are considered necessary for a fair presentation of the consolidated financial statements of the Company as of June 30, 2021. The operating results presented herein are not necessarily
an indication of the results that may be expected for the year. The condensed consolidated financial statements should be read in conjunction with the Company’s audited Consolidated Financial Statements included in its Annual Report on Form
10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021.
The Contribution was completed on March 2, 2021 and the combination of MOR and Forian was accounted for as a transaction between entities under common control
pursuant to ASC 805-50. Accordingly, the combination of Forian and MOR results in a change in reporting entity and the financial statements are presented as though the combination of Forian and MOR occurred as of the beginning of the periods
presented. Additionally, the results of Helix are included in the accompanying condensed consolidated financial statements beginning on March 2, 2021, the Merger Closing Date.
Note 3
|
SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
|
Principles of Consolidation
The condensed consolidated financial statements of the Company include the
accounts of (i) Medical Outcomes Research Analytics, LLC and its wholly owned subsidiaries COR Analytics, LLC and MOR Analytics, LLC, and (ii) Helix Technologies, Inc. and its wholly owned subsidiaries Helix TCS, LLC, Security Consultants
Group, LLC, Boss Security Solutions, LLC, Security Grade Protective Services, Ltd., Bio-Tech Medical Software, Inc, BT UCS, Inc., Engeni LLC (including Engeni S.A., which is 99% owned by Engeni LLC), Green Tree International, Inc. and AIE Exchange Canada, Inc. All intercompany transactions have been eliminated in consolidation. The financial
results of Helix and its subsidiaries are included in the condensed consolidated financial statements beginning on March 2, 2021, the Merger Closing Date.
Use of Estimates
Preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates, judgements and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses together with amounts disclosed in related notes to the financial statements. Certain of the Company’s
estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is possible that the external factors could have an effect on the Company’s estimates and could cause actual results
to differ from those estimates.
Fair
Value of Financial Instruments
The Company measures the fair value of financial assets and liabilities based
on the guidance of ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value
measurements.
ASC 820 defines fair value as the exchange price that would be received for an
asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an ordinary transaction between market participants on the measurement date. ASC 820 also establishes a fair value
hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
Level 1 — quoted prices in active markets for identical assets or liabilities;
Level 2 — quoted prices for similar assets and liabilities in active markets
or inputs that are observable; and
Level 3 — inputs that are unobservable.
The carrying value of the Company’s financial instruments, such as cash,
marketable securities, accounts receivable and accrued liabilities and other liabilities approximate fair values due to the short-term nature of these instruments.
Cash and Cash Equivalents and Credit Risk
The Company considers all cash accounts that are not subject to withdrawal
restrictions and highly liquid investments with a maturity of three months or less, when purchased, as cash and cash equivalents.
The Company maintains cash with major financial institutions. Cash held at
U.S. bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution.
The portion of deposits in excess of FDIC coverage is not protected by such insurance and represents a credit risk to the Company. At times, the Company’s deposits exceed this coverage.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of an allowance
for doubtful accounts. The Company determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and economic conditions.
Outstanding account balances are reviewed individually for collectability. The
allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Allowance for doubtful accounts was $269,325 and $0 at June 30, 2021 and December 31, 2020,
respectively.
Management charges account balances against the allowance after all means of
collection have been exhausted and the potential for recovery is considered remote.
Long-Lived Assets, Including Definite Lived Intangible
Assets
Long-lived assets, other than goodwill and other indefinite-lived intangibles,
are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. Definite-lived
intangible assets primarily consist of customer relationships, software technology and trade names. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its
undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to
fair value.
Goodwill
Goodwill, which represents the excess of purchase price over the fair value of
net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based test. The Company reviews goodwill for possible impairment annually during the
fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable.
The impairment model prescribes a two-step method for
determining goodwill impairment. However, an entity is permitted to first assess qualitative factors to determine whether the two-step goodwill impairment test is necessary.
The qualitative factors considered by Forian may include, but are not limited to, general
economic conditions, the Company’s outlook, market performance of the Company’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it
is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. In the first step, the Company determines the fair value of its reporting unit using a
discounted cash flow analysis. If the net book value of the reporting unit exceeds its fair value, the Company then performs the second step of the impairment test, which requires allocation of the reporting unit’s fair value to all of its
assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations with any residual fair value being allocated to goodwill. An impairment charge is recognized when the implied fair value of
the Company’s goodwill is less than its carrying amount. No impairment losses have been recognized during the periods
presented.
Business Combinations
The Company accounts for its business combinations under the provisions of ASC
Topic 805-10, Business Combinations (“ASC 805-10”), which requires that the purchase method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including
non-controlling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from
goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business
combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the
acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent
consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value
are recognized in earnings.
Revenue Recognition
The Company recognizes revenue in accordance with Financial Accounting
Standards Board (“FASB”) Topic 606 - Revenue from Contracts with Customers (“ASC 606”).
Under ASC 606, the Company recognizes revenue when the customer obtains
control of promised goods or services, in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC 606:
(i) identify contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v)
recognize revenues when (or as) the Company satisfies a performance obligation. ASC 606-10-32-32 requires the determination of the price at which the Company would sell individual products or services to a customer. The Company does not always
have sufficient data or experience related to the terms and pricing for products and services when components are sold on a standalone basis. In instances where insufficient data exists, the Company recognizes the contractual fees ratably over
the term of the arrangement. In instances where a customer has limited operating history or the customer has recently been formed, management may determine that it is prudent to recognize only the first year’s fees ratably over the first year
of the term, more often than not resulting in the recognition of a lower amount of revenue during the first year. Performance obligations that are distinct and remain undelivered would not be recognized until the end of the contract provided
that the consideration is guaranteed. No significant judgements affect the determination of the amount and timing of revenue.
The Company generates revenue from three categories of product offerings: Information and Software, Services and Other.
In 2020, the revenue generated by the Company was exclusively from Information
and Software relating to MOR. In 2021, the Company also began to recognize Information and Software, Services and Other revenues related to its acquisition of Helix on March 2, 2021.
In most Information and Software contracts, payments are scheduled throughout
the term and the contract may include one or more of the following performance obligations: (i) the provision of historical and/or current information as agreed upon, (ii) access to the information through a hosting provider, (iii) access to
and use of software products (iv) installation and training and (v) access to the Company’s analytical team throughout the term of the agreement, as agreed upon.
Information and Software contracts do not always have distinct pricing
assigned to each performance obligation; rather, the price is bundled and the total bundled pricing is invoiced throughout the term of the agreement, with the exception of contracts for software products which provide separate pricing for
implementation and training of such products.
The Company recognizes revenue resulting from Information and Software
pursuant to agreements under which the Company receives payments for providing the customer access to its products over the contract period. The Company satisfies its performance obligations throughout the term of the contract. Any payments
received prior to satisfying performance obligations are deferred and recognized as the performance obligations are satisfied. There are no variable considerations or financing component under such contracts. Prices are typically fixed, but
certain contracts can also include royalties in excess of fixed fees. There were $62,500 of royalties in excess of fixed fees for the
six months ended June 30, 2021. Invoicing under contracts is set forth in an invoicing schedule as part of the contract and payments are typically due within 30 days.
Services revenues are primarily from contracts with government agencies and
revenue is recognized upon completion of the various milestones within the contract. In the event that a contract does not specifically allocate revenue to the satisfaction of specific performance obligations or milestones, the purchase price
of the contracts is allocated based on the percentage of time spent, or expected to be spent, to meet each performance obligation. Initial customization of the software to meet state specific requirements and the training to appropriately
utilize the software are generally recognized upon completion of the customization and acceptance by the state agency. Support and service revenues are then recognized over a predetermined period of time as defined in the contract. Contract
renewals may include an annual service fee that is recognized over the time period defined in the contract.
Other revenues are primarily from security monitoring services offerings and
the provision of web marketing services. Contracts for these services have a stated transaction price for monthly services and are recognized as the services are provided.
Contract acquisition costs, which consist of sales commissions paid or
payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. $8,162 and $53,784 of such costs were
capitalized as of June 30, 2021 and December 31, 2020, respectively. There are no significant judgements affecting the determination of the amount and timing of the related revenue.
In the event the Company has not satisfied all performance obligations on its
contracts with customers, any amounts of unbilled revenue or excess costs are recorded as contract assets and contract liabilities.
Contract assets result when the cumulative revenue recognized exceeds the
cumulative invoicing under a contract. The value of the differential is reflected in Contract assets and represents the value of the revenue that was not billed to customers as of the balance sheet date.
Contract liabilities (“Deferred Revenue”) result when cumulative receipts
under a contract for the same performance obligation exceeds the total revenue recognition and such excess is reflected in Deferred Revenue and represents the value of the performance obligations to be satisfied after June 30, 2021.
The following are the contract balances as of and for the six months ended
June 30, 2021:
Contract assets
|
||||
Balance at January 1, 2021
|
$ | 196,701 | ||
Contract assets acquired from Helix
|
277,088 |
|||
Add: Revenue recognized from related contract assets
|
879,097 |
|||
Less: Contract acquisition costs amortized during the six months ended June 30, 2021
|
(45,622 | ) | ||
Less: Payments received during the six months ended June 30, 2021
|
(724,667 | ) | ||
Balance at June 30, 2021
|
$ | 582,597 | ||
|
||||
Contract liabilities (Deferred
Revenue)
|
||||
Balance at January 1, 2021
|
$ | 158,884 | ||
Contract liabilities assumed from Helix
|
320,936 |
|||
Add: Payments received during the six months ended June 30, 2021
|
1,410,760 | |||
Less: Revenue recognized during the six months ended June 30, 2021
|
(1,231,686 | ) | ||
Balance at June 30, 2021
|
$ | 658,894 |
Segment Information
ASC 280, Segment Reporting (“ASC 280”), establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial
information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the chief
executive officer, who reviews the financial performance and the results of operations of the segments prepared in accordance with U.S. GAAP when making decisions about allocating resources and assessing performance of the Company.
Customer Concentration
The Company did not have any
customers that exceeded 10% of total revenue for the three and six months ended June 30, 2021. The Company had a
customer
that accounted for 46% and 48%
of total revenue for the three and six months ended June 30, 2020, respectively. The Company believes that this customer is ultimately replaceable, and any disruption associated with this customer would only have a short-term impact on the
business.Concentration
of Vendors
The Company has licensed certain information
assets from a third party as a key input to certain of the Company’s Information and Software Products. Licensing fees to this vendor represented less than 10% of the Company’s operating expenses for the three and six months ended June 30,
2021, respectively, and the three and six months ended June 30, 2020, respectively. This vendor is critical to the business. The Company believes that while this vendor is ultimately replaceable, any disruption associated with this vendor could
have a material short-term impact on the business.
Property and Equipment, Net
Property and equipment are stated at cost, net of accumulated depreciation,
which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which are 1 to 7 years. Maintenance and repairs are charged to
operations as incurred.
The Company reviews for the impairment of long-lived assets annually and
whenever events and or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when the present value of estimated future cash flows expected to result from the use of
the asset and its eventual disposition is less than the carrying value. There were no impairment losses recognized during the
three and six months ended June 30, 2021 and 2020, respectively.
Software Development Costs
The Company accounts for costs incurred in the development of computer
software in accordance with ASC Subtopic 350-40, Intangibles – Goodwill and Other – Internal-Use Software. Costs incurred in the application development stage are subject to capitalization and
subsequent amortization and possible impairment. Application development stage costs were not material for the Company. Product development costs are primarily personnel related to activities for design and evaluating software development,
testing, bug fixes, and other maintenance activities. Product development costs are expensed as incurred. The Company capitalized software development costs of $266,410 and $0, as of June 30, 2021 and December 31, 2020, respectively.
Contingencies
Occasionally, the Company may be involved in claims and legal proceedings
arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and
assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of
complex judgments about future events and can rely heavily on estimates and assumptions.
Advertising
Advertising costs are expensed as incurred and included in sales and marketing
expenses and amounted to $16,063 and $20,998
for the three and six months ended June 30, 2021, respectively, and $0 and $0 for the three and six months ended June 30, 2020, respectively.
Foreign Currency
The local currency is the functional currency for one entity’s operations
outside the United States. Assets and liabilities of these operations are translated to U.S. dollars at the exchange rate in effect at the end of each period. Income statement accounts are translated at the average exchange rate prevailing
during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included as a component of other comprehensive loss within stockholders’ equity. Gains and losses from foreign currency
transactions are included in net loss for the period.
Net Loss per Share
Net loss per share of common stock is computed by dividing net loss by the
weighted average number of common shares outstanding during the period. At June 30, 2021, the Company had potentially dilutive securities that could be exercised or converted into common stock. Refer to Note 13 for the Company’s disclosure on
such potential dilution. Further, as the Company has incurred net losses for the three and six months ended June 30, 2021 and 2020, respectively, the diluted loss per share is the same as basic loss per share for the periods presented.
Distinguishing Liabilities from Equity
The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, to
classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is
mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.
Once the Company determines that a financial instrument should not be
classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity
classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.
Initial Measurement
The Company records its financial instruments classified as liability,
temporary equity or permanent equity at issuance at the fair value, or cash received.
Subsequent Measurement – Financial instruments classified as liabilities
The Company records the fair value of its financial instruments classified as
liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other expense/income.
Stock-based Compensation
The Company’s 2020 Equity Incentive Plan (“2020 Plan”) permits the grant of
stock options, restricted stock awards and/or restricted stock units. A total of 4,000,000 shares of the Company’s common stock are authorized and reserved for issuance under the 2020 Plan. Stock options represent the right to purchase the
Company’s common stock at the exercise price on the date of grant of the stock option at a future date. Restricted stock awards are grants of shares of our common stock. Restricted stock units represent the right to receive shares of our common
stock on future specified dates. Stock options, restricted stock awards and units granted contain restrictions that cause them to be subject to substantial risk of forfeiture and restrict their exercise, sale or other transfer by the grantee
until they vest. The terms of the stock options, restricted stock awards and units granted under the 2020 Plan are determined by the Board of Directors in the agreement evidencing the award, including the number of shares, period of restriction
or vesting schedule and other terms. The fair value of the stock options, restricted stock awards and units is based on the underlying grant date fair value of the Company’s common stock. The fair value is then expensed over the requisite
service periods of the awards, net of forfeitures, which is generally the service period and the related amount is recognized in the condensed consolidated statements of operations.
Income Taxes
MOR was organized as a limited liability company and became a wholly owned
subsidiary of the Company upon completion of the Merger with Helix on March 2, 2021. As a result, the Company was treated as a partnership for federal and state income tax purposes through March 2, 2021. Accordingly, the Company’s taxable
income, deductions, assets and liabilities are reported by the members on their respective income tax returns. Therefore, no
provision for federal or state income tax has been made by the Company for all business activity from its inception through March 2, 2021.
After March 2, 2021, the Company accounts for income taxes under the asset and
liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and
liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances
are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has an incurred net operating loss for financial-reporting and tax-reporting purposes. Accordingly, for federal and state income tax
purposes, the benefit for income taxes has been offset entirely by a valuation allowance against the related federal and state deferred tax asset for the period since March 2, 2021.
Tax contingencies are recorded, if needed, to address potential exposure
involving tax positions the Company has taken that could be challenged by tax authorities. These potential exposures could result from applications of various statutes, rules, regulations and interpretations. Any estimates of tax contingencies
contain assumptions and judgments about potential actions by taxing jurisdictions. Any interest and penalties related to uncertain tax positions would be included as part of the income tax provision. The Company’s conclusions regarding
uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of or changes in tax laws, regulations and interpretations thereof as well as other factors.
Recent Accounting Pronouncements
The Company has considered all recently issued accounting pronouncements and
does not believe the adoption of such pronouncements will have a material impact on its financial statements.
Note 4 |
BUSINESS COMBINATION
|
On March 2, 2021,
pursuant to the Merger and the Merger Agreement, Forian acquired 100% of the issued and outstanding capital stock, options and warrants of
Helix.
The total purchase
consideration for the Merger was $18,454,784. The purchase consideration is equal to the product of (i) the total outstanding Helix common
shares and common share equivalents for in-the-money warrants to purchase Helix common stock and vested stock options multiplied by the merger exchange ratio of 0.05 shares of Company common stock for 1 share of Helix common stock and (ii) $2.158 per share, which
represented the fair value of Company common stock on the acquisition date.
The Merger was accounted
for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the Merger. These values are subject to change as the Company completes its determination
of the fair value of assets acquired and liabilities assumed.
The following table summarizes the preliminary
purchase price allocations relating to the Merger:
Total purchase price
|
$
|
18,454,784
|
||
Assets acquired:
|
||||
Cash
|
1,310,977
|
|||
Accounts receivable, net
|
488,453
|
|||
Prepaid expenses
|
215,064
|
|||
Contract assets
|
277,088
|
|||
Other assets
|
450,000
|
|||
Property and equipment
|
146,559
|
|||
Software Technology
|
5,279,000
|
|||
Trade Names and Trademarks
|
386,000
|
|||
Customer Relationships
|
5,243,000
|
|||
Right of use assets
|
1,082,684 | |||
Deposits and other assets
|
582
|
|||
Total assets acquired
|
$
|
14,879,407
|
||
Liabilities assumed:
|
||||
Accounts payable and accrued liabilities
|
$
|
2,428,675
|
||
Short-term lease liabilities
|
295,364 | |||
Deferred revenues
|
320,936
|
|||
Warrant liability
|
1,247,715
|
|||
Notes payable and financing arrangements
|
20,801
|
|||
Other long-term liabilities
|
812,044
|
|||
Total liabilities assumed
|
$
|
5,125,535
|
||
Estimated fair value of net assets acquired:
|
$
|
9,753,872
|
||
Goodwill
|
$
|
8,700,912
|
The preliminary estimates for useful lives of
the identified intangibles are 8 years for Trade Names and Trademarks, 5 years for Customer Relationships and 2 and 7 years for Software Technology Intangibles with a weighted average useful life of 5.47 years.
Transaction costs
incurred in connection with the Business Combination amounted to approximately $0 and $1,210,279 during the three and six months ended June 30, 2021, respectively.
Unaudited Pro Forma Results
The following table represents the revenue, net loss and loss per
share effect of the acquired company, as reported in our pro forma basis as if the acquisition occurred on January 1, 2020. These pro forma results are not necessarily indicative of the results that would have occurred if the acquisition had occurred
on the first day of the periods presented, nor does the pro forma financial information purport to represent the results of operations for future periods.
For the Three Months Ended
June 30,
|
For the Six Months Ended
June 30,
|
|||||||||||||||
Description
|
2021
|
2020
|
2021
|
2020
|
||||||||||||
Revenues
|
4,547,985
|
2,948,881
|
8,177,502
|
6,072,716
|
||||||||||||
Net loss
|
(7,134,196
|
)
|
(2,907,056
|
)
|
(14,388,547
|
)
|
(6,140,962
|
)
|
||||||||
Net loss per share:
|
||||||||||||||||
Basic and diluted-as pro forma (unaudited)
|
$
|
(0.26
|
)
|
$
|
(0.11
|
)
|
$
|
(0.47
|
)
|
$
|
(0.24
|
)
|
The pro forma financial
information for all periods presented above has been calculated after adjusting the results of the Company and Helix to reflect the business combination accounting effects resulting from this acquisition, including the amortization expense from
acquired intangible assets included in the pro forma financial information presented above. The Forian historical condensed consolidated financial statements have been adjusted in the pro forma combined financial statements to give effect to pro
forma events that are directly attributable to the business combination and factually supportable. The pro forma financial information is for informational purposes only and is not indicative of the results of operations that would have been achieved
if the acquisition had taken place at the beginning of the periods presented.
Note 5
|
MARKETABLE SECURITIES
|
Marketable securities are stated at estimated fair value based upon current market quotes (level 1 inputs) and are classified as available-for-sale. Realized gains
and losses are included in investment income. Unrealized gains and losses are immaterial and therefore the Company has presented such amounts within Investment income in the Statement of Operations. The Company invests in short-term U.S.
Treasuries and money market mutual funds. As of June 30, 2021 and 2020, the fair value of these investments approximated cost.
Note 6
|
PREPAID EXPENSES
|
The Company has various agreements which require upfront and periodic payments. The Company records the expenses related to these agreements ratably over the
annual terms. As of June 30, 2021 and December 31, 2020, the Company’s balance sheet reflected other prepaid expenses of $930,172 and
$120,979, respectively, relating to various software licenses and insurance policies with durations ranging from 3 months to 1 year.
Note 7
|
PROPERTY AND EQUIPMENT, NET
|
As of June 30, 2021 and December 31, 2020, property and equipment were comprised of the following:
June 30,
2021
|
December 31,
2020
|
|||||||
Unaudited
|
||||||||
Personal computing equipment
|
$
|
103,478
|
$
|
55,767
|
||||
Furniture and equipment
|
131,065
|
—
|
||||||
Software development costs
|
266,410
|
—
|
||||||
Vehicles
|
25,876
|
—
|
||||||
Total
|
526,829
|
55,767
|
||||||
Less: Accumulated depreciation and amortization
|
(44,595
|
)
|
(9,409
|
)
|
||||
Property and equipment, net
|
$
|
482,234
|
$
|
46,358
|
Depreciation and amortization expense for the three and six months ended June 30, 2021 was $28,275 and $38,986, respectively, and for the three and six
months ended June 30, 2020 was $1,419 and $1,873, respectively.
Note 8
|
INTANGIBLE ASSETS, NET
|
The following table summarizes the Company’s intangible assets as of June 30, 2021:
|
Estimated
Useful Life
(Years)
|
Gross Carrying
Amount at
March 2, 2021
|
Accumulated
Amortization
|
Net Book
Value at
6/30/2021
|
||||||||||||
Customer Relationships
|
5
|
$
|
5,243,000
|
$
|
(343,896
|
)
|
$
|
4,899,104
|
||||||||
Software Technology
|
2
|
1,170,000
|
(191,855
|
)
|
978,145
|
|||||||||||
Software Technology
|
7
|
4,109,000
|
(192,511
|
)
|
3,916,489
|
|||||||||||
Tradenames and Trademarks
|
8
|
386,000
|
(15,824
|
)
|
370,176
|
|||||||||||
|
$
|
10,908,000
|
$
|
(744,086
|
)
|
$
|
10,163,914
|
The Company uses the straight-line method to determine the amortization expense for its definite lived intangible assets. Amortization expense related to the purchased intangible assets was $567,213 and $744,086 for the
three and six months ended June 30, 2021, respectively, and $0 for the three and six months ended June 30, 2020.
The estimated future amortization expense for the next five years and thereafter is as follows:
Years Ending December 31,
|
Future amortization expense
|
|||
2021
|
$
|
1,134,425
|
||
2022
|
2,268,850
|
|||
2023
|
1,784,495
|
|||
2024
|
1,683,850
|
|||
2025
|
1,683,850
|
|||
Thereafter
|
1,608,444
|
|||
Total
|
$
|
10,163,914
|
Note 9
|
ACCRUED EXPENSES
|
As of June 30, 2021 and December 31, 2020, accrued expenses were comprised of the following:
June 30,
2021
|
December 31,
2020
|
|||||||
Employee compensation
|
1,376,218
|
346,720
|
||||||
Accrued expenses
|
970,349
|
8,825
|
||||||
Transaction-related
|
—
|
125,196
|
||||||
Total
|
$
|
2,346,567
|
$
|
480,741
|
Transaction-related accrued expenses are associated with the Merger. See Note 4.
Note 10
|
WARRANT LIABILITY
|
In conjunction with the
Merger, outstanding warrants to purchase Helix common stock were converted to warrants to purchase Company common stock. As the warrant holders have the option to receive cash in lieu of common stock in certain circumstances, the Company
determined that the warrants require classification as a liability pursuant to ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity. In accordance with the applicable accounting
guidance, the outstanding warrants are recognized as a warrant liability on the condensed consolidated balance sheet and are measured at their inception date fair value (the closing date of the Merger) and subsequently re-measured at each
reporting period with changes being recorded in the condensed consolidated statement of operations. As of June 30, 2021, the Company had 97,058
warrants outstanding classified as liabilities.
The fair value of the Company’s warrant liability was calculated using the
Black-Scholes model and the following assumptions:
As of June 30, 2021
|
||||
Fair value of company’s common stock
|
$
|
12.57
|
||
Dividend yield
|
0
|
% | ||
Expected volatility
|
121% - 153
|
%
|
||
Risk Free interest rate
|
0.06% - 0.56
|
%
|
||
Expected life (years)
|
2.33
|
|||
Exercise price
|
|
$8.00 - $28.00
|
||
Fair value of financial instruments - warrants
|
$
|
752,888
|
The change in fair value of the financial instruments – warrants is as
follows:
Amount
|
||||
Balance as of January 1, 2021
|
$
|
—
|
||
Fair value of warrant liability assumed in connection
with Helix Merger
|
1,247,715
|
|||
Change in fair value of warrant liability
|
(494,827
|
)
|
||
Balance as of June 30, 2021
|
$
|
752,888
|
Amount
|
||||
Balance as of April 1, 2021
|
$
|
624,088
|
||
Change in fair value of warrant liability
|
128,800
|
|||
Balance as of June 30, 2021
|
$
|
752,888
|
Note 11
|
STOCK-BASED COMPENSATION
|
Restricted Stock Awards and Restricted Stock Units
Unvested equity interests of MOR were converted into restricted common stock
of the Company based upon the Exchange Ratio of 1.7776 Forian shares for each 1 MOR unit, subject to any adjustments required under
the Contribution Agreement. The
information regarding the 2020 Plan below is presented as though the combination occurred as of the beginning of the periods presented.
Number of
Restricted Shares
and Units
|
Weighted Average
Grant Date Fair Value
Per Share
|
|||||||
Unvested at January 1, 2020
|
|
1,237,396
|
$
|
0.62
|
||||
Issued
|
2,191,869
|
1.21
|
||||||
Vested
|
1,729,589
|
0.72
|
||||||
Canceled
|
—
|
—
|
||||||
Unvested at December 31, 2020
|
1,699,676
|
1.28
|
||||||
Issued
|
404,000
|
11.86
|
||||||
Vested
|
343,125
|
0.03
|
||||||
Canceled
|
—
|
—
|
||||||
Unvested at June 30, 2021
|
|
1,760,551
|
$
|
2.73
|
The 1,760,551 of unvested awards at June 30, 2021 consists of 404,000
restricted stock units and 1,356,551 shares of restricted stock.
Stock Options
As part of the Merger (see Note 4), the Company assumed the Helix TCS, Inc.
Omnibus Stock Incentive Plan and the Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan, each as amended, pursuant to which options exercisable at prices between $2.00 and $51.80 per share for 455,089 shares of Company common stock were outstanding. The value attributable to service subsequent to the Merger will be recognized as
compensation cost by the Company.
The fair value of the stock options was estimated using the Black-Scholes
option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgement. The assumptions at the
inception date are as follows:
June 30,
2021
|
||||
Exercise Price
|
$
|
2.00 to $51.80
|
||
Fair value of Company common stock
|
$
|
9.39 to $22.90
|
||
Dividend yield
|
0
|
%
|
||
Expected volatility
|
126.0
|
% | ||
Risk Free interest rate
|
1.0% to 1.1
|
% | ||
Expected life (years) remaining
|
0 to 9.72
|
Stock option activity for the period ended June 30, 2021 is as follows:
Shares Underlying
Options
|
Weighted Average
Exercise Price
|
Weighted Average
Remaining
Contractual Term
(in years)
|
||||||||||
Outstanding at January 1, 2021
|
—
|
$
|
—
|
|
||||||||
Options assumed in Helix Merger
|
455,089
|
$
|
15.13
|
3.69
|
||||||||
Granted
|
3,264,714
|
$
|
13.21
|
9.72
|
||||||||
Exercised
|
(12,437
|
)
|
$
|
3.02
|
1.77
|
|||||||
Forfeited and expired
|
(4,037
|
)
|
$
|
14.91
|
6.13
|
|||||||
Outstanding at June 30, 2021
|
3,703,329
|
$
|
14.25
|
8.96
|
||||||||
Vested options at June 30, 2021
|
455,089
|
$
|
15.13
|
3.69
|
Stock Compensation Expense
The grant date fair value per share for the stock options granted was $12.39 and $0.02 for the six months
ended June 30, 2021 and 2020, respectively.
At June 30, 2021, the total unrecognized stock compensation expense related to
unvested stock option awards and restricted stock awards and units granted was $41,878,995, which the Company expects to recognize
over a weighted-average period of approximately 3.69 years. Stock compensation expense for the three and six months ended June 30, 2021 and 2020
is as follows:
Three Months Ended June 30,
|
Six Months Ended June 30, |
|||||||||||||||
2021
|
2020
|
2021 | 2020 | |||||||||||||
Cost of revenue
|
4,656
|
—
|
4,656 |
— |
||||||||||||
Research and development
|
83,099
|
3,222
|
137,989 | 5,798 | ||||||||||||
Sales and marketing
|
174,919
|
1,128
|
206,663 | 2,029 | ||||||||||||
General and administrative
|
2,488,873
|
2,192
|
3,268,865 | 3,943 | ||||||||||||
Total | 2,751,547 | 6,542 | 3,618,173 | 11,770 |
Note
12
|
STOCKHOLDERS’
EQUITY
|
The Condensed Consolidated
Statement of Stockholders’ Equity reflects the exchange of MOR Members Equity for Company common stock as of the beginning of the periods presented. See Note 2.
All of MOR’s Class A, Class B vested profit
interests’ units, Series S, Series S-1, and vested Restricted Class B units were converted to Forian common stock on March 2, 2021 based upon the exchange ratio of 1.7776 Forian shares to 1 MOR member unit, subject to adjustment pursuant to the Contribution Agreement. Unvested Class B profit interest units, unvested restricted Class B units and options to acquire Restricted
Class B Units were converted to unvested restricted Company common stock on March 2, 2021 based upon the exchange ratio of 1.7776 Forian
shares to 1 MOR member unit, subject to adjustment pursuant to the Contribution Agreement. The applicable vesting provisions of such MOR units carried over to the restricted Company common stock.
In December 2020, MOR completed a Series S-1
financing with cash proceeds of $13,000,000 in exchange for 3,388,947 Series S-1 preferred units.
In March 2020, MOR completed a Series S
financing with cash proceeds of $3,300,000 and converted a promissory note of $184,300 in exchange for 3,078,276 Series S preferred units.
In 2019 and 2020, Class B profit interest
units, restricted Class B units and options to acquire Class B units were issued to employees, consultants and advisors.
In March 2021, the Company issued warrants to
purchase 17,031 shares of the Company’s common stock at a per-share purchase price equal to $0.01. The warrants terminate after a period of 2 years from the
issuance date. The warrants were issued in exchange for services provided with a fair value of $389,976 included in transaction related
expenses for the six months ended June 30, 2021.
On April 16, 2021, the Company raised
proceeds of $11,968,652, net of transaction expenses of $31,348, resulting from the sale of 1,194,743 shares of Company common stock at
an average purchase price equal to $10.21 per share to a select group of institutional and accredited investors. Investors included both
unaffiliated investors as well as directors of the Company. Directors purchased 560,461 shares of common stock at a purchase price of $11.33 per share, which amount represented the consolidated closing bid price of Company common stock as reported by the Nasdaq Stock Market LLC on April
9, 2021, the last trading day prior to execution of the securities purchase agreement. Unaffiliated investors purchased 631,282 shares
of Company common stock at a purchase price of $8.95 per share, which price was negotiated on April 9, 2021, and represents an
approximately 15% discount to the preceding day’s volume weighted average price.
See Note 4 for additional details on shares
issued pursuant to the Merger.
Note 13
|
NET LOSS PER SHARE
|
The following table sets
forth the computation of the basic and diluted net loss per share:
For the Three Months Ended
June 30,
|
For the Six Months Ended
June 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Net loss attributable to common shareholders
|
$
|
(7,134,196
|
)
|
$
|
(791,639
|
)
|
$
|
(11,625,843
|
)
|
$
|
(1,466,775
|
)
|
||||
Net loss per share attributable to common shareholders:
|
||||||||||||||||
Basic
|
$
|
(0.23
|
)
|
$
|
(0.06
|
)
|
$
|
(0.42
|
)
|
$
|
(0.13
|
)
|
||||
Diluted
|
$
|
(0.23
|
)
|
$
|
(0.06
|
)
|
$
|
(0.42
|
)
|
$
|
(0.13
|
)
|
||||
Weighted average common shares outstanding:
|
||||||||||||||||
Basic
|
30,996,735
|
13,797,652
|
27,534,359
|
11,066,456
|
||||||||||||
Diluted
|
30,996,735
|
13,797,652
|
27,534,359
|
11,066,456
|
The following table sets forth the outstanding potentially
dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:
For the Three and Six
Months Ended
June 30,
|
||||||||
2021
|
2020
|
|||||||
Potentially dilutive securities:
|
||||||||
Warrants
|
124,087
|
—
|
||||||
Stock options
|
3,703,329
|
—
|
||||||
Unvested Restricted Stock Awards and Units
|
1,760,551
|
1,846,338
|
||||||
Total |
5,587,967 | 1,846,338 |
Note 14
|
RELATED PARTY TRANSACTIONS
|
On May 6, 2019, MOR entered into an arrangement with family trusts controlled by Max Wygod and Martin Wygod, directors of MOR, to issue two separate promissory notes (“Note” or “Notes”) entitling MOR to secure up to $100,000 per Note to fund operations. The Notes had no interest rate and were due on the sooner of the initial closing of MOR’s Series S Preferred Unit financing or December 31, 2020. In
March 2020, in connection with MOR’s Series S Preferred Unit financing, the aggregate outstanding balance of the Notes of $184,300,
was converted, at the option of the holders, into 295,501 shares of Company common stock.
Adam Dublin, Chief Strategy Officer, was previously a consultant for a current vendor of MOR. Mr. Dublin’s consultancy with the vendor ended on December 11, 2020
and the parties have not agreed to renew the agreement. Pursuant to Mr. Dublin’s consulting agreement with the vendor, Mr. Dublin received payments from the vendor for the three and six months ended June 30, 2021 and 2020 of $90,065 and $196,149, and $183,675 and $244,725, respectively.
On April 16, 2021, the Company raised net proceeds of $11,968,652
resulting from the sale of Company common stock to a select group of institutional and accredited investors, which included directors of the Company. See Note 12 for additional information.
Note 15
|
COMMITMENTS AND CONTINGENCIES
|
Operating Leases
The Company accounts for leases in accordance with ASC 842. All contracts are evaluated to determine whether or not they represent a lease.
A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company has operating leases primarily consisting of facilities with remaining lease terms of one year to five years. The lease
term represents the period up to the early termination date unless it is reasonably certain that the Company will not exercise the early termination option. Certain leases include rental payments that are adjusted periodically based on
changes in consumer price and other indices.
Leases are classified as finance or operating in accordance with the guidance in ASC 842. The Company does not hold any finance leases.
The Company is obligated under operating lease agreements for office facilities in (i) Florida (two), (ii) Washington, (iii) Colorado and (iv) Argentina that expire in (i) December 2021 and 2024, (ii) December 2022, (iii) February 2026 and (iv) December 2021,
respectively. The Company also has three short-term leases related to offices in Pennsylvania, Massachusetts and Virginia. These
short-term leases are currently leased on a month-to-month basis. A short-term lease is a lease with a term of 12 months or less and does not include the option to purchase the underlying asset that we would expect to exercise. The Company
has elected to adopt the short-term lease exemption in ASC 842 and as such have not recognized a “right of use” asset or lease liability for these three
short-term leases.
The Company’s lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is
determined based on information available at lease commencement date for purposes of determining the present value of lease payments.
Supplemental cash flow information and non-cash activity related to leases for the six months ended June 30, 2021 and 2020 were as follows:
|
Six Months Ended June 30,
|
|||||||
|
2021
|
2020
|
||||||
Cash used in operating leases
|
$
|
120,615 |
$
|
— |
||||
ROU assets obtained in exchange for lease obligations
|
$
|
94,010 |
$
|
— |
ROU lease assets and lease liabilities for the Company’s operating leases were recorded in the condensed consolidated balance sheet as follows:
|
As of June 30,
2021
|
As of December 31,
2020
|
||||||
Right of use assets, net
|
$
|
988,674
|
$
|
—
|
||||
Short-term operating lease liabilities
|
|
264,330
|
|
—
|
||||
Long-term operating lease liabilities
|
$
|
737,701
|
$
|
—
|
||||
Total lease liabilities
|
$
|
1,002,031
|
$
|
—
|
||||
Weighted average remaining lease term (in years)
|
3.47
|
|
||||||
Weighted average discount rate
|
8.5
|
%
|
0.0
|
% |
The total rent expense was $108,476 and $3,152 for the three months ended June 30, 2021 and 2020, respectively, and $129,554 and 8,146 for the six months ended June 30, 2021 and 2020,
respectively.
The components of lease expense were as follows for each of the period presented:
Three Months Ended June 30,
|
Six Months Ended June 30,
|
||||||||||||||
2021
|
2020
|
2021
|
2020
|
||||||||||||
Operating lease expense
|
$
|
81,935
|
|
$
|
—
|
|
$
|
109,247
|
|
$
|
—
|
||||
Short-term lease expense |
$ | 26,541 | $ | 3,152 | $ | 34,493 | $ | 8,146 | |||||||
Total operating lease costs
|
$ | 108,476 | $ | 3,152 | $ | 143,740 | $ | 8,146 |
Future lease payments included in the measurement of lease liabilities on the condensed consolidated balance sheet as of June 30, 2021, for the following five
fiscal years and thereafter were as follows:
As of June 30,
2021
|
||||
2021
|
$
|
160,363
|
||
2022
|
308,470
|
|||
2023
|
286,670
|
|||
2024
|
291,161
|
|||
2025
|
85,726
|
|||
Thereafter
|
14,288
|
|||
Total future minimum lease payments
|
$
|
1,146,678
|
||
Less imputed interest
|
(144,647
|
)
|
||
Total
|
$
|
1,002,031
|
Service Agreements
The Company entered into certain service agreements that provide for future minimum payments. The terms of these agreements vary in length. The following
table shows the remaining payment obligations under these licenses as of June 30, 2021:
June 30,
2021
|
December 31,
2020
|
|||||||
Unaudited
|
||||||||
Year ending December 31, 2021
|
$
|
—
|
$
|
533,488
|
||||
Year ending December 31, 2022
|
272,188
|
272,188
|
||||||
$
|
272,188
|
$
|
805,676
|
From time to
time, the Company may be involved in claims that arise during the ordinary course of business. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from important business matters
and initiatives, negatively impacting our overall operations. Although the results of litigation and claims cannot be predicted with certainty, the Company does not currently have any pending litigation to which it is a party or to which its
property is subject that we believe to be material, except for:
Legal
Proceedings
Kenney, et al. v. Helix TCS, Inc.
On July 20, 2017, one
former employee of Helix filed a lawsuit in the United States District Court for the District of Colorado alleging violations of the Fair Labor Standards Act on behalf of himself and other employees. The plaintiff seeks damages for Helix’s
alleged failure to compensate employees appropriately for the overtime hours they worked as purported “non-exempt” employees. The matter has been conditionally certified as a collective action and the court has authorized the plaintiff to
send notice and consent forms to putative class members. Notice and consent forms have been sent. The period for returning consent forms has ended. No decision has been made on the merits of the claim. The case is in the early stages of
discovery. The Company will vigorously defend the claims in the lawsuit.
Audet v. Green Tree International, et. al.
On February 14, 2020, John Audet filed a complaint in 15th Judicial Circuit in and for Palm Beach County, Florida against multiple parties,
including Green Tree International (“GTI”), an indirect subsidiary of Forian, claiming that he owned 10% of GTI. The Company
believes the lawsuit is wholly without merit and will vigorously defend the claims in the lawsuit. As of June 30, 2021, the case is in the process of discovery, with several depositions set for August 2021. Pursuant to a recent hearing, the
case is currently set for trial on an
-week trial docket beginning on January 17, 2022. The parties are working on a
proposed scheduling order to reflect the Court’s recent ruling as to the rescheduling of the trial. In addition, mediation is in the process of being scheduled.Helix Stockholder Lawsuits
Beginning on February 16, 2021, four lawsuits were
filed by purported Helix stockholders (captioned Dillion v. Helix Technologies, Inc., et al., No. 1:21-cv-01365 (filed February 16, 2021 in the United States District Court for the Southern District of
New York) (the “Dillion Complaint”); Baros v. Helix Technologies, Inc., et al., No. 1:21-cv-01425 (filed February 17, 2021 in the United States District Court for the Southern District of New York) (the
“Baros Complaint”); Anderson v. Helix Technologies, Inc., et al., No. 1:21-cv-00464 (filed February 17, 2021 in the United States District Court for the District of Colorado) (the “Anderson Complaint”);
and Robinson v. Helix Technologies, Inc., et al., No. 1:21-cv-00484 (filed February 18, 2021 in the United States District Court for the District of Colorado) (the “Robinson Complaint” and, together
with the Dillion Complaint, the Anderson Complaint and the Baros Complaint, the “Stockholder Complaints”)). The Stockholder Complaints were filed against (a) Helix and (b) the members of Helix’s board of directors (the “Individual Defendants”)
and the Baros Complaint was also filed against Forian, MOR and Merger Sub. The Stockholder Complaints generally allege that the defendants violated Section 14(a) of the Exchange Act, by, among other things, failing to disclose material
information in the Proxy Statement regarding the sales process, reconciliation of certain financial projections regarding Helix certain inputs underlying Management Planning, Inc.’s financial analysis, and potential conflicts of interest of
involving Helix’s insiders. The Stockholder Complaints also allege the Individual Defendants (and the Baros Complaint alleges Forian, Merger Sub and MOR) violated Section 20(a) of the Exchange Act as controlling persons who had the ability to
prevent the Proxy Statement from being materially false and misleading. The Stockholder Complaints seek, among other things, an injunction against the consummation of the transactions contemplated by the Merger Agreement and an award of costs
and expenses, including a reasonable allowance for attorneys’ and experts’ fees. Despite seeking an injunction in the complaints, none of the plaintiffs followed up with a motion to enjoin the transactions. On March 11, 2021, the Robinson
Complaint was voluntarily dismissed. The remaining three complaints have not been served, and there has been no activity on any of
them since the complaints were filed.
Nykiah Thomas v. Security Consultants Group, LLC d/b/a Helix TCS, Helix Technologies, Inc. and Shamson Sundra
On
July 16, 2021, Nykiah Thomas, individually and on behalf of M’Seiya Thomas, a minor, filed a complaint in the District Court, City and County of Denver, Colorado, against Security Consultants Group, LLC d/b/a Helix TCS and Helix
Technologies, Inc., subsidiaries of Forian, and Shamson Sundra, a former employee of Security Consultants Group, LLC, alleging negligence in the performance of security services in connection with a school shooting at STEM School Highlands
Ranch that occurred on May 7, 2019. The case is in the early stages of discovery. The Company will vigorously defend the claims in the lawsuit.
Note
16
|
SEGMENT
RESULTS
|
ASC 280-10-50 requires use of the “management
approach” model for segment reporting. The management approach is based on the way a company’s management organized segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and
services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.
Operating segments are defined as components
of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s
chief operating decision-making group is composed of the chief executive officer and the chief financial officer. The Company operates in three
segments, Information & Software, Services and Other.
Asset information by operating segment is not
presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s unaudited condensed consolidated financial
statements.
The following represents selected
information for the Company’s reportable segments:
Three months ended June 30,
|
Six months ended June 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Information and Software
|
||||||||||||||||
Revenue
|
$
|
3,763,671
|
$
|
108,750
|
$
|
5,172,649
|
$
|
175,417
|
||||||||
Costs and expenses
|
6,514,714
|
598,220
|
10,152,316
|
$
|
1,169,773
|
|||||||||||
Loss from operations
|
(2,751,043
|
)
|
(489,470
|
)
|
(4,979,667
|
)
|
(994,356
|
)
|
||||||||
Total other income/(expense)
|
—
|
—
|
—
|
—
|
||||||||||||
Net loss before income taxes
|
(2,751,043
|
)
|
(489,470
|
)
|
(4,979,667
|
)
|
(994,356
|
)
|
||||||||
Services
|
||||||||||||||||
Revenue
|
$
|
492,336
|
$
|
—
|
$
|
588,647
|
$
|
—
|
||||||||
Costs and expenses
|
305,830
|
—
|
386,120
|
—
|
||||||||||||
Loss from operations
|
186,506
|
—
|
202,527
|
—
|
||||||||||||
Total other income/(expense)
|
—
|
—
|
—
|
—
|
||||||||||||
Net loss before income taxes
|
186,506
|
—
|
202,527
|
—
|
||||||||||||
Other
|
||||||||||||||||
Revenue
|
$
|
291,978
|
$
|
—
|
$
|
407,298
|
$
|
—
|
||||||||
Costs and expenses
|
390,100
|
—
|
469,987
|
—
|
||||||||||||
Loss from operations
|
(98,122
|
)
|
—
|
(62,689
|
)
|
—
|
||||||||||
Total other income/(expense)
|
(244
|
)
|
—
|
(332
|
)
|
—
|
||||||||||
Net income before income taxes
|
(98,366
|
)
|
—
|
(63,021
|
)
|
—
|
||||||||||
Centrally Managed Costs
|
||||||||||||||||
Revenue
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
||||||||
Costs and expenses
|
4,322,291
|
302,913
|
7,261,636
|
478,126
|
||||||||||||
Loss from operations
|
(4,322,291
|
)
|
(302,913
|
)
|
(7,261,636
|
)
|
(478,126
|
)
|
||||||||
Total other income/(expense)
|
(149,002
|
)
|
744
|
475,954
|
5,707
|
|||||||||||
Net loss before income taxes
|
(4,471,293
|
)
|
(302,169
|
)
|
(6,785,682
|
)
|
(472,419
|
)
|
||||||||
Totals
|
||||||||||||||||
Revenue
|
$
|
4,547,985
|
$
|
108,750
|
$
|
6,168,594
|
$
|
175,417
|
||||||||
Costs and expenses
|
11,532,935
|
901,133
|
18,270,059
|
1,647,899
|
||||||||||||
Loss from operations
|
(6,984,950
|
)
|
(792,383
|
)
|
(12,101,465
|
)
|
(1,472,482
|
)
|
||||||||
Total other income/(expense)
|
(149,246
|
)
|
744
|
475,622
|
5,707
|
|||||||||||
Net loss
|
$
|
(7,134,196
|
)
|
$
|
(791,639
|
)
|
$
|
(11,625,843
|
)
|
$
|
(1,466,775
|
)
|
Approximately 98% of revenues were attributable to customers in the United States for the three and six months ended June 30, 2021. All of the Company’s
revenues were attributable to customers in the United States for the three and six months ended June 30, 2020.
Note 17
|
SUBSEQUENT EVENTS
|
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued.
Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
Cautionary Statement for Forward-Looking Information
The following discussion of our financial condition and results of operations for the three and six months ended June 30, 2021 and 2020,
respectively, should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon
current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a
result of a number of factors, including those set forth under Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 31, 2021. We use words such as “anticipate,”
“estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.
Unless expressly indicated or the context requires otherwise, the terms “Forian”, the “Company”, “we”, “us”, and “our” refer to Forian Inc.
Overview
The Company was initially incorporated in Delaware on October 15, 2020 as a wholly owned subsidiary of Medical Outcomes Research Analytics, LLC (“MOR”), which was founded in Delaware on May 6, 2019, in connection
with the Business Combination described below. On October 16, 2020, the Company entered into a definitive agreement with Helix Technologies, Inc. (“Helix”) and MOR, pursuant to which DNA Merger Sub, Inc., a wholly owned subsidiary of the Company
(“Merger Sub”), merged with and into Helix, with Helix surviving the merger as a wholly owned subsidiary of the Company (the “Merger”). On March 2, 2021, the Company entered into a definitive agreement with the equity holders of MOR, pursuant to
which the equity holders of MOR contributed their interests in MOR to the Company in exchange for shares of Company common stock (the “Contribution” and together with the Merger, the “Business Combination”). Following consummation of the Business
Combination on March 2, 2021, the Company became the parent company of both Helix and MOR. Helix provides traceability and point of sale technology, analytics solutions and other products to customers within each vertical of the cannabis industry
to help them improve the performance of their business.
The Company provides innovative software solutions, proprietary data and predictive analytics to optimize the operational and financial
performance of our customers. Given the prior experience of our management team, our initial focus is on stakeholders within the healthcare and cannabis industries. However, we believe the application of our offerings across other verticals to
enhance the transparency and efficacy of our customers’ relationships with their communities and customers is equally compelling.
The Company represents the unique convergence of proprietary healthcare, consumer and cannabis data, SaaS analytics, innovative data management capabilities and intelligent data science with a leading cannabis
technology platform yielding the combined power to drive innovation and transparency across the industries we serve. In MOR, there was early recognition of the opportunity to bring the sophistication of proven data science technology and analytics
solutions to a prominent cannabis technology platform provider, creating innovation in both the applications that are key to supporting customer success within the cannabis industry and to the data science powered insights that drive healthcare and
other mature regulated growth industries. In Helix, there was realization that the capability set of a technology solutions provider within more evolved sectors together with the track record of the MOR management team offered a unique opportunity
to enhance the value that Helix brings to its cannabis customers and to the industry generally.
The Company’s mission is to provide our customers with the best-in-class critical technology services through a single integrated
Forian platform that enables our customers within the healthcare and cannabis industries to operate their businesses more safely, efficiently and profitably and to serve our customers and our customers’ stakeholders and constituencies more
comprehensively.
A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a pandemic by the World Health Organization. Our business has largely operated in a work-from-home environment
since the inception of the pandemic and, as a result, has experienced limited business disruption to date. Our management team continues to focus on the highest level of safety measures to protect our employees. We have not experienced a material
impact to our financial results to date, however, COVID-19 continues to present significant uncertainty in the future economic outlook for our customers and the markets we serve.
Financial Operations Overview
The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.
Revenues
Revenues are derived from Information and Software Products, Services and Other Products. Information and Software revenues are generated
from licensing fees for our proprietary information and software products. The Company recognizes revenues from Information and Software products as performance obligations under customer contracts are satisfied. Services revenues are primarily
from contracts with government agencies and revenue is recognized upon completion of the various milestones within the contract. Other revenues are primarily from security monitoring services offerings and the provision of web marketing services.
Contracts for these services have a stated transaction price for monthly services and are recognized as the services are provided.
Cost of Revenues
Cost of revenue is generated from direct costs associated with the delivery of our products and services to our customers. The cost of
revenue relates primarily to labor costs, hosting and infrastructure costs and client service team costs. We record the cost of direct fulfillment as cost of revenue. Infrastructure and licensed data costs, which are shared across all projects or
groups of projects, are not charged to cost of revenue.
Research and Development
Research and development expenses consist primarily of employee-related expenses, subcontractor and third-party consulting fees, and hosted infrastructure costs. We continue to focus our research and development
efforts on adding new features and applications to our product offerings. Once our prototypes are proven, we begin to capitalize costs that qualify with the associated development rather than recording those costs as research and development.
Sales and Marketing
Sales and marketing expense is primarily salaries and related expenses, including commissions, for our sales, marketing and product
management staff. Marketing program costs are also recorded as sales and marketing expense including advertising, market research and events (such as trade shows, corporate communications, brand building, etc.). The Company plans to continue to
invest in marketing and sales by expanding our selling and marketing staff, building brand awareness, attracting new clients and sponsoring additional marketing events. The timing of these marketing events will affect our marketing costs in any
particular quarter.
General and Administrative Expenses
General and administrative expenses include salaries and benefits and other costs of departments serving administrative functions, such
as executives, finance and accounting and human resources. In addition, general and administrative expense includes non-personnel costs, such as professional fees, legal fees, accounting and finance advisory fees and other supporting corporate
expenses not allocated to cost of revenue, product and development or sales and marketing.
Depreciation and Amortization Expenses
Depreciation and Amortization relate to long lived assets used in our business. Depreciation expense relates primarily to furniture and
equipment, computers and vehicles. Amortization expense relates primarily to identifiable intangibles of acquired companies.
Transaction Related Expenses
Transaction related expenses relate to the acquisition of Helix on March 2, 2021 and include professional, legal, accounting and finance advisory fees and other direct expenses.
Critical Accounting Policies and Use of Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which we have prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as
critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates – which also would have been reasonable – could have been used.
On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.
Critical accounting policies and estimates are further discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 31, 2021.
Results of Operations for the three and six months ended June 30, 2021 and 2020
The following table summarizes our condensed results of operations for the periods indicated:
For the Three Months Ended,
|
For the Six Months Ended,
|
|||||||||||||||
June 30, 2021
|
June 30, 2020
|
June 30, 2021
|
June 30, 2020
|
|||||||||||||
Revenues
|
$
|
4,547,985
|
$
|
108,750
|
$
|
6,168,594
|
$
|
175,417
|
||||||||
Costs and Expenses
|
||||||||||||||||
Cost of Revenues
|
1,232,790
|
—
|
1,690,676
|
—
|
||||||||||||
Research and development
|
1,949,926
|
426,398
|
3,447,764
|
815,391
|
||||||||||||
Sales and marketing
|
1,177,035
|
55,978
|
1,776,010
|
111,044
|
||||||||||||
General and administrative
|
6,577,696
|
326,832
|
9,362,258
|
629,085
|
||||||||||||
Depreciation and amortization
|
595,488
|
1,419
|
783,072
|
1,873
|
||||||||||||
Transaction related expenses
|
—
|
90,506
|
1,210,279
|
90,506
|
||||||||||||
Loss from operations
|
$
|
(6,984,950
|
)
|
$
|
(792,383
|
)
|
$
|
(12,101,465
|
)
|
$
|
(1,472,482
|
)
|
Comparison of Three Months Ended June 30, 2021 and 2020
Revenues
Revenues for the three months ended June 30, 2021 were $4,547,985, which represented an increase of $4,439,235, compared to total
revenue of $108,750 for the three months ended June 30, 2020. These revenues were primarily from Information and Software products. The increase is due to the inclusion of revenues from the Helix acquisition, which contributed 71% of the
increase, and higher revenues from the Company’s Information products, which contributed 29% of the increase. Revenues from the Company’s Information products increased $1,286,881 or 1183% compared to the three months ended June 30, 2020.
Cost of Revenues
Cost of revenues increased by $1,232,790 for the three months ended June 30, 2021 from $0 for the three months ended June 30, 2020. The
increase related to direct costs related to the delivery of revenues. This increase was primarily from increased revenues of the Company’s Information and Software products. The increase is due to the inclusion of the Helix acquisition, which
contributed 92% of the increase, and higher cost of revenues from the Company’s Information products, which contributed 8% of the increase.
Research and Development
Research and development expenses for the three months ended June 30, 2021 were $1,949,926, which represented an increase of $1,523,528
compared to total research and development expenses of $426,398 for the three months ended June 30, 2020. The increase is due to higher R&D expenses related to scaling the Company’s products, which contributed 80% of the increase, stock-based
compensation expenses related to equity awards granted to new Company employees after we became a public company on March 2, 2021, which contributed approximately 5% of the increase, and the inclusion of the Helix acquisition, which contributed
15% of the increase.
Sales and Marketing
Sales and marketing expenses for the three months ended June 30, 2021 were $1,177,035, which represented an increase of $1,121,057
compared to total sales and marketing expenses of $55,978 for the three months ended June 30, 2020. The increase is due to higher expenses related to scaling the Company’s products, which contributed 60% of the increase, stock-based compensation
expenses related to equity awards granted to new Company employees after we became a public company on March 2, 2021, which contributed approximately 16% of the increase, and the inclusion of the Helix acquisition, which contributed 24% of the
increase.
General and Administrative
General and administrative expenses for the three months ended June 30, 2021 were $6,577,696, which represented an increase of
$6,250,864 compared to general and administrative expenses of $326,832 for the three months ended June 30, 2020. The increase is due to higher expenses related to scaling the Company’s management organization, which contributed 40% of the
increase, stock-based compensation expenses related to equity awards granted to key Helix employees and new Company hires after we became a public company on March 2, 2021, which contributed approximately 40% of the increase, and the inclusion of
the Helix acquisition, which contributed 20% of the increase.
Transaction Related Expenses
Transaction related expenses for the three months ended June 30, 2021 were $0, which represented a decrease of $90,506 compared to
transaction related expenses of $90,506 for the three months ended June 30, 2020. These expenses related to the acquisition of Helix, which was completed on March 2, 2021.
Comparison of Six Months Ended June 30, 2021 and 2020
Revenues
Revenues for the six months ended June 30, 2021 were $6,168,594, which represented an increase of $5,993,177 compared to total
revenue of $175,417 for the six months ended June 30, 2020. These revenues were primarily from Information and Software products. The increase is due to the inclusion of revenues from the Helix acquisition since March 2, 2021, which contributed
70% of the increase, and higher revenues from the Company’s products, which contributed 30% of the increase. Revenues from the Company’s Information products increased $1,794,050 or 1023% compared to the six months ended June 30, 2020.
Cost of Revenues
Cost of revenues increased by $1,690,676 for the six months ended June 30, 2021 from $0 for the six months ended June 30, 2020. The
increase related to direct costs related to the delivery of revenues. This increase was primarily from increased revenues of the Company’s Information and Software products. The increase is due to the inclusion of the Helix acquisition since
March 2, 2021, which contributed 87% of the increase, and higher cost of revenues from the Company’s Information products, which contributed 13% of the increase.
Research and Development
Research and development expenses for the six months ended June 30, 2021 were $3,447,764, which represented an increase of $2,632,373
compared to total research and development expenses of $815,391 for the six months ended June 30, 2020. The increase is due to higher R&D expenses related to scaling the Company’s products, which contributed 83% of the increase, stock-based
compensation expenses related to equity awards granted to new Company employees after we became a public company on March 2, 2021, which contributed approximately 5% of the increase, and the inclusion of the Helix acquisition since March 2,
2021, which contributed 12% of the increase.
Sales and Marketing
Sales and marketing expenses for the six months ended June 30, 2021 were $1,776,010, which represented an increase of $1,664,966
compared to total sales and marketing expenses of $111,044 for the six months ended June 30, 2020. The increase is due to higher expenses related to scaling the Company’s products, which contributed 67% of the increase, stock-based compensation
expenses related to equity awards granted to new Company employees after we became a public company on March 2, 2021, which contributed approximately 12% of the increase, and the inclusion of the Helix acquisition since March 2, 2021, which
contributed 21% of the increase.
General and Administrative
General and administrative expenses for the six months ended June 30, 2021 were $9,362,258, which represented an increase of $8,733,173
compared to general and administrative expenses of $629,085 for the six months ended June 30, 2020. The increase is due to higher expenses related to scaling the Company’s management organization, which contributed 45% of the increase,
stock-based compensation expenses related to equity awards granted to key Helix employees and new Company hires after we became a public company on March 2, 2021, which contributed approximately 37% of the increase, and the inclusion of the Helix
acquisition since March 2, 2021, which contributed 18% of the increase.
Transaction Related Expenses
Transaction related expenses for the six months ended June 30, 2021 were $1,210,279, which represented an increase of $1,119,773
compared to transaction related expenses of $90,506 for the six months ended June 30, 2020. These expenses related to the acquisition of Helix, which was completed on March 2, 2021.
Non-GAAP Financial Measures
In this Quarterly Report on Form 10-Q, we have provided a non-GAAP measure, which we define as financial information that has not been prepared in accordance with U.S. GAAP. The non-GAAP financial measure provided
herein is earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) presented on both a historical basis and a “pro forma” basis reflecting the acquisition of Helix as of the beginning of the periods presented. Adjusted EBITDA
should be viewed as supplemental to, and not as an alternative for net income or loss calculated in accordance with U.S. GAAP (referred to below as “Net loss”).
Adjusted EBITDA is used by our management as an additional measure of our Company’s performance for purposes of business decision-making, including developing budgets, managing expenditures and evaluating potential
acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our Company’s financial results that may not be shown solely by period-to-period comparisons of net income. In addition,
we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our Company’s performance. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded
items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income, as well as trends in those
items contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations.
We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate
investor understanding of decisions made by management in light of the performance metrics used in making those decisions. In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of net
loss to Adjusted EBITDA, helps investors make comparisons between our company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or
different forms of employee compensation. However, Adjusted EBITDA is not intended as a substitute for comparisons based on net loss. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP
measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding U.S. GAAP measures provided by each company under
applicable SEC rules.
The following is an explanation of the items excluded by us from Adjusted EBITDA but included in net loss:
● |
Depreciation and Amortization. Depreciation and amortization expense is a non-cash expense relating to capital expenditures and intangible assets arising from acquisitions that
are expensed on a straight-line basis over the estimated useful life of the related assets. We exclude depreciation and amortization expense from Adjusted EBITDA because we believe that (i) the amount of such expenses in any specific period
may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired tangible and
intangible assets. Accordingly, we believe that this exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that the use of tangible and intangible assets
contributed to revenue in the periods presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.
|
● |
Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees. We believe that excluding the
effect of stock-based compensation from Adjusted EBITDA assists management and investors in making period-to-period comparisons in our Company’s operating performance because (i) the amount of such expenses in any specific period may not
directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with
acquisitions. Additionally, we believe that excluding stock-based compensation from Adjusted EBITDA assists management and investors in making meaningful comparisons between our Company’s operating performance and the operating performance
of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees
whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.
|
● |
Interest and Investment Income and Expense. Interest and investment income is associated with the level of marketable debt securities and other interest bearing accounts in
which we invest, and interest expense is related to our debt assumed in our acquisition of Helix related to the financing certain of its fixed assets. Interest and investment income and expense can vary over time due to a variety of
financing transactions, changes in interest rates, cash used to fund operations and capital expenditures and acquisitions that we have entered into or may enter into in the future. We exclude interest and investment income and expense from
Adjusted EBITDA (i) because these items are not directly attributable to the performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating
performance and (ii) to assist management and investors in making comparisons to companies with different capital structures. Investors should note that interest income and expense will recur in future periods.
|
● |
Other Items. We engage in other activities and transactions that can impact our net loss. In the periods being reported, these other items included, (i) change in fair value of
warrant liability which related to warrants assumed in the acquisition of Helix; (ii) transaction related expenses which consist of professional fees and other expenses incurred in connection with the acquisition of Helix; and (iii) other
income which consists of profits on marketable security investments. We exclude these other items from Adjusted EBITDA because we believe these activities or transactions are not directly attributable to the performance of our business
operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that some of these other items may recur in future periods.
|
● |
Income tax expense. MOR was organized as a limited liability company until the completion of the Helix acquisition. As a result, we were treated as a partnership for federal and
state income tax purposes through March 2, 2021, and our taxable income and losses are reported by our members on their individual tax returns for such period. Therefore, we did not record any income tax expense or benefit through March 2,
2021. We expect to incur a net loss for financial reporting and income tax reporting purposes for this year. Accordingly, any benefit for federal and state income taxes benefit has been entirely offset by a valuation allowance against the
related deferred tax net assets. We exclude the income tax expense from Adjusted EBITDA (i) because we believe that the income tax expense is not directly attributable to the underlying performance of our business operations and,
accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes.
|
Limitations on the use of Non-GAAP financial measures
There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with U.S. GAAP and may be different from non-GAAP financial measures provided by other
companies.
The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as
they reflect the exercise of judgments by management about which items are adjusted to calculate our non-GAAP financial measures. We compensate for these limitations by analyzing current and future results on a U.S. GAAP basis as well as a non-GAAP
basis and also by providing U.S. GAAP measures in our public disclosures.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP. We encourage investors and others to review our financial
information in its entirety, not to rely on any single financial measure to evaluate our business and to view our non-GAAP financial measures in conjunction with the most directly comparable U.S. GAAP financial measures.
The following tables reconciles the specific items excluded from U.S. GAAP metrics in the calculation of non-GAAP metrics for the periods shown below.
Historical (Unaudited)
|
Historical (Unaudited)
|
|||||||||||||||
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Revenues:
|
||||||||||||||||
Information and Software
|
$
|
3,763,671
|
$
|
108,750
|
$
|
5,172,649
|
$
|
175,417
|
||||||||
Services
|
492,336
|
$
|
—
|
588,647
|
—
|
|||||||||||
Other
|
291,978
|
$
|
—
|
407,298
|
—
|
|||||||||||
Total revenues
|
$
|
4,547,985
|
$
|
108,750
|
$
|
6,168,594
|
$
|
175,417
|
||||||||
Net loss
|
$ |
(7,134,196
|
)
|
$
|
(791,639
|
)
|
$
|
(11,625,843
|
)
|
$
|
(1,466,775
|
)
|
||||
Depreciation & amortization
|
595,488
|
1,419
|
783,072
|
1,873
|
||||||||||||
Stock based compensation expense
|
2,751,547
|
6,542
|
3,618,173
|
11,770
|
||||||||||||
Change in fair value of warrant liability
|
128,800
|
—
|
(494,827
|
)
|
—
|
|||||||||||
Loss on impairment of goodwill
|
—
|
—
|
—
|
—
|
||||||||||||
Transaction related expenses
|
—
|
90,506
|
1,210,279
|
90,506
|
||||||||||||
Interest and investment income, net
|
20,446
|
(744
|
)
|
19,205
|
(5,707
|
)
|
||||||||||
Other income
|
—
|
—
|
—
|
—
|
||||||||||||
Income tax expense
|
—
|
—
|
—
|
—
|
||||||||||||
Adjusted EBITDA
|
$
|
(3,637,915
|
)
|
$
|
(693,916
|
)
|
$
|
(6,489,941
|
)
|
$
|
(1,368,333
|
)
|
Three Months ended June 30, 2021 (Historical)
Adjusted EBITDA
Adjusted EBITDA for the three months ended June 30, 2021 was a loss of $3,637,915 compared to a loss of $693,916 for the three months
ended June 30, 2020, an increase of $2,943,999. The increase is primarily due to investments in product development, customer service, infrastructure and human capital and the inclusion of the Helix acquisition since March 2, 2021.
Six Months ended June 30, 2021 (Historical)
Adjusted EBITDA
Adjusted EBITDA for the six months ended June 30, 2021 was a loss of $6,489,941 compared to a loss of $1,368,333 for the six months
ended June 30, 2020, an increase of $5,121,608. The increase is primarily due to investments in product development, customer service, infrastructure and human capital and the inclusion of Helix.
|
Pro Forma (Unaudited)
|
Pro Forma (Unaudited)
|
||||||||||||||
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
||||||||||||||
|
2021
|
2020
|
2021 (1)
|
2020
|
||||||||||||
Revenues:
|
||||||||||||||||
Information and Software
|
$
|
3,763,671
|
$
|
2,378,605
|
$
|
6,801,326
|
$
|
4,784,373
|
||||||||
Services
|
492,336
|
283,732
|
822,336
|
651,455
|
||||||||||||
Other
|
291,978
|
286,544
|
553,840 |
636,888
|
||||||||||||
Total revenues
|
$
|
4,547,985
|
$
|
2,948,881
|
$
|
8,177,502
|
$
|
6,072,716
|
||||||||
|
||||||||||||||||
Net loss
|
$
|
(7,134,196
|
)
|
$
|
(2,907,056
|
)
|
$
|
(14,388,547
|
)
|
$
|
(6,140,962
|
)
|
||||
|
||||||||||||||||
Depreciation & amortization
|
595,488
|
589,688
|
1,204,300
|
1,184,848
|
||||||||||||
Stock based compensation expense
|
2,751,547
|
322,314
|
3,781,116
|
1,071,604
|
||||||||||||
Change in fair value of warrant liability
|
128,800
|
41,847
|
721,397
|
(615,678
|
)
|
|||||||||||
Loss on impairment of goodwill
|
—
|
—
|
—
|
1,369,978
|
||||||||||||
Transaction related expenses
|
—
|
141,385
|
2,096,054
|
175,810
|
||||||||||||
Interest and investment income, net
|
20,446
|
170,960
|
24,060
|
668,803
|
||||||||||||
Other income
|
—
|
—
|
(55,006
|
)
|
—
|
|||||||||||
Income tax expense
|
—
|
—
|
—
|
—
|
||||||||||||
|
||||||||||||||||
Adjusted EBITDA
|
$
|
(3,637,915
|
)
|
$
|
(1,640,862
|
)
|
$
|
(6,616,626
|
)
|
$
|
(2,285,597
|
)
|
(1) The Pro Forma information for the six months ended June 30, 2021 above include revisions to non-GAAP financial measure amounts included in our Quarterly Report on Form 10-Q for three months ended March 31, 2021,
as filed with the SEC on May 17, 2021. The net impact of such revisions to Adjusted EBITDA was $(147,596).
Three Months ended June 30, 2021 (Pro Forma)
Revenues
Pro forma revenues for the three months ended June 30, 2021 were $4,547,985, which represented an increase of $1,599,104 compared to total revenue of $2,948,881 for the three months ended June 30, 2020. The increase
was primarily due to growth in the number of customers utilizing the Company’s Information products.
Adjusted EBITDA
Pro forma Adjusted EBITDA for the three months ended June 30, 2021 was a loss of $3,637,915 compared to a loss of $1,640,862 for the
three months ended June 30, 2020, an increase of $1,997,053. The increase is primarily due to investments in product development, customer service, infrastructure and human capital.
Six Months ended June 30, 2021 (Pro Forma)
Revenues
Pro forma revenues for the six months ended June 30, 2021 were $8,177,502, which represented an increase of $2,104,786 compared to
total revenue of $6,072,716 for the six months ended June 30, 2020. The increase was primarily due to growth in the number of customers utilizing these products.
Adjusted EBITDA
Pro forma Adjusted EBITDA for the six months ended June 30, 2021 was a loss of $6,616,626 compared to a loss of $2,285,597 for the
six months ended June 30, 2020, an increase of $4,331,029. The increase is primarily due to investments in product development, customer service, infrastructure and human capital.
Liquidity and Capital Resources
Since the Company’s inception in 2019, most of the Company’s resources have been devoted to scaling its research and development, sales and marketing, and management infrastructure. The Company’s operations have been
financed primarily from the cash proceeds received from equity issuances. The Company expects to continue to fund its operations and future acquisitions through a combination of cash flow generated from operating activities, debt financing, and/or
additional equity issuances. To date, the Company has generated limited revenues from the licensing of information products. The Company has incurred losses and generated negative cash flows from operations since inception. As of June 30, 2021, the
Company’s principal source of liquidity was cash, which totaled $4,763,324 and marketable securities which totaled $12,505,118.
Cash Flows
The following table summarizes selected information about our sources and uses of cash and cash equivalents for the periods presented:
For the Six Months Ended,
|
||||||||
June 30, 2021
|
June 30, 2020
|
|||||||
Net cash used in operating activities
|
$
|
(8,248,764
|
)
|
$
|
(1,518,139
|
)
|
||
Net cash used in investing activities
|
(18,269
|
)
|
(1,144,884
|
)
|
||||
Net cash provided by financing activities
|
12,294,355
|
3,315,700
|
||||||
Effect of foreign exchange rate changes on cash
|
70,539
|
—
|
||||||
Net increase in cash and cash equivalents
|
$
|
4,097,861
|
$
|
652,677
|
Net Cash Used in Operating Activities
Net cash used in operating activities increased by $6,730,625 for the six months ended June 30, 2021 compared to the six months ended June 30, 2020. The increase was primarily the result of scaling up the Company’s
operations from the initial start-up phase.
Net Cash Used in Investing Activities
Net cash used in investing activities decreased by $1,126,615 for the six months ended June 30, 2021 compared to the six months ended
June 30, 2020. This is the result of an increase in additions to property and equipment of $314,366 and an increase in the purchase of marketable securities of $9,616,140, offset by an increase in the sale of marketable securities of $9,746,144
and cash acquired of $1,310,977 as part of the Business Combination.
Net Cash Provided by Financing Activities
Net cash provided by financing activities increased by $8,978,655 for the six months ended June 30, 2021 compared to the six months ended June 30, 2020. The increase was primarily related to the cash proceeds
received from the Company’s equity issuance in April 2021.
Off Balance Sheet Arrangements
The Company does not have relationships with other organizations or process any transactions that would constitute off balance sheet arrangements.
Recent Accounting Pronouncements
The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.
See Note 3 in the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information about recent accounting pronouncements.
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk
|
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
Item 4. |
Controls and Procedures
|
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports
filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our
management, including our chief executive officer (who is also our principal executive officer), and our chief financial officer (who is also our principal financial and accounting officer), to allow for timely decisions regarding required
disclosure. In accordance with Rules 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the
effectiveness of our disclosure controls and procedures as of June 30, 2021, which is the end of the three-month period covered by this Quarterly Report on Form 10-Q.
We identified material weaknesses in our internal controls over financial reporting as disclosed in Item 9A of our Annual Report on
Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021. Our chief executive officer and chief financial officer therefore concluded that our disclosure controls and procedures as of the fiscal quarter ended
June 30, 2021 remain ineffective to the extent of the material weaknesses identified.
We are committed to remediating the control deficiencies that gave rise to the material weaknesses, certain of which were the result of
the evaluation of MOR as the financial successor to Helix for the twelve-months ended December 31, 2021. Our management is responsible for implementing changes and improvements to internal control over financial reporting and for remediating the
control deficiencies that gave rise to the material weaknesses we identified. With oversight from our Audit Committee, we have taken steps to remediate the internal control deficiencies and expect to implement further remediation actions during
2021 that we believe will improve our internal control over financial reporting. Certain improvements to our internal control over financial reporting occurred as a consequence of the Merger (e.g., additional finance resources and protocols
employed by Helix), supplemented by our engagement of outside firms to assist us with additional accounting expertise and with the review of our internal controls framework for our compliance with the Sarbanes Oxley Act of 2002, as amended. Until
the remediation actions are fully implemented and the operational effectiveness of related internal controls is validated through testing, the material weaknesses noted above will continue to exist.
Notwithstanding the identified material weaknesses, our management, including our chief executive officer and chief financial officer, has determined, based on the procedures we have performed, that the consolidated
financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial condition, results of operations and cash flows at June 30, 2021 and for the periods presented in accordance with U.S. GAAP.
Changes in Internal Control Over Financial Reporting
Our remediation efforts for material weaknesses previously reported were ongoing during the three months ended June 30, 2021, as described in Item 9A of our 2020 Annual Report on Form 10-K for the fiscal year ended
December 31, 2020, as filed with the SEC on March 31, 2021. There were no other material changes in our internal control over financial reporting that occurred during the six months ended June 30, 2021 that materially affected, or that are
reasonably likely to materially affect, our internal control over financial reporting.
Part II — OTHER INFORMATION
Item 1. |
Legal Proceedings
|
From time to time we may be involved in claims that arise during the ordinary course of business. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from
important business matters and initiatives, negatively impacting our overall operations. Although the results of litigation and claims cannot be predicted with certainty, we do not currently have any pending litigation to which we are a party or to
which our property is subject that we believe to be material, except for:
Kenney, et al. v. Helix TCS, Inc.
On July 20, 2017, one former employee of Helix filed a lawsuit in the United States District Court for the District of Colorado alleging violations of the Fair Labor Standards Act on behalf of himself and other
employees. The plaintiff seeks damages for Helix’s alleged failure to compensate employees appropriately for the overtime hours they worked as purported “non-exempt” employees. The matter has been conditionally certified as a collective action and
the court has authorized the plaintiff to send notice and consent forms to putative class members. Notice and consent forms have been sent. The period for returning consent forms has ended. No decision has been made on the merits of the claim. The
case is in the early stages of discovery. The Company will vigorously defend the claims in the lawsuit.
Audet v. Green Tree International, et. al.
On February 14, 2020, John Audet filed a complaint in 15th Judicial Circuit in and for Palm Beach County, Florida against multiple parties, including Green Tree International (“GTI”), an indirect subsidiary of
Forian, claiming that he owned 10% of GTI. We believe the lawsuit is wholly without merit and will vigorously defend the claims in the lawsuit. As of June 30, 2021, the case is in the process of discovery, with several depositions set for August
2021. Pursuant to a recent hearing, the case is currently set for trial on an eight-week trial docket beginning on January 17, 2022. The parties are working on a proposed scheduling order to reflect the Court’s recent ruling as to the rescheduling
of the trial. In addition, mediation is in the process of being scheduled.
Helix Stockholder Lawsuits
Beginning on February 16, 2021, four lawsuits were filed by purported Helix stockholders (captioned Dillion v. Helix Technologies, Inc., et al., No. 1:21-cv-01365 (filed
February 16, 2021 in the United States District Court for the Southern District of New York) (the “Dillion Complaint”); Baros v. Helix Technologies, Inc., et al., No. 1:21-cv-01425 (filed February 17, 2021
in the United States District Court for the Southern District of New York) (the “Baros Complaint”); Anderson v. Helix Technologies, Inc., et al., No. 1:21-cv-00464 (filed February 17, 2021 in the United
States District Court for the District of Colorado) (the “Anderson Complaint”); and Robinson v. Helix Technologies, Inc., et al., No. 1:21-cv-00484 (filed February 18, 2021 in the United States District
Court for the District of Colorado) (the “Robinson Complaint” and, together with the Dillion Complaint, the Anderson Complaint and the Baros Complaint, the “Stockholder Complaints”)). The Stockholder Complaints were filed against (a) Helix and (b)
the members of Helix’s board of directors (the “Individual Defendants”) and the Baros Complaint was also filed against Forian, MOR and Merger Sub. The Stockholder Complaints generally allege that the defendants violated Section 14(a) of the
Exchange Act, by, among other things, failing to disclose material information in the Proxy Statement regarding the sales process, reconciliation of certain financial projections regarding Helix certain inputs underlying Management Planning, Inc.’s
financial analysis, and potential conflicts of interest of involving Helix’s insiders. The Stockholder Complaints also allege the Individual Defendants (and the Baros Complaint alleges Forian, Merger Sub and MOR) violated Section 20(a) of the
Exchange Act as controlling persons who had the ability to prevent the Proxy Statement from being materially false and misleading. The Stockholder Complaints seek, among other things, an injunction against the consummation of the transactions
contemplated by the Merger Agreement and an award of costs and expenses, including a reasonable allowance for attorneys’ and experts’ fees. Despite seeking an injunction in the complaints, none of the plaintiffs followed up with a motion to enjoin
the transactions. On March 11, 2021, the Robinson Complaint was voluntarily dismissed. The remaining three complaints have not been served, and there has been no activity on any of them since the complaints were filed. We will vigorously defend the
claims in the remaining pending Stockholder Complaints.
Nykiah Thomas v. Security Consultants Group, LLC d/b/a Helix TCS, Helix Technologies, Inc. and Shamson Sundra
On July 16, 2021, Nykiah Thomas, individually and on behalf of M’Seiya Thomas, a minor, filed a complaint in the District Court, City and County of Denver, Colorado, against Security Consultants Group, LLC d/b/a
Helix TCS and Helix Technologies, Inc., subsidiaries of Forian, and Shamson Sundra, a former employee of Security Consultants Group, LLC, alleging negligence in the performance of security services in connection with a school shooting at STEM
School Highlands Ranch that occurred on May 7, 2019. The case is in the early stages of discovery. The Company will vigorously defend the claims in the lawsuit.
Item 1A. |
Risk Factors
|
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds
|
On April 12, 2021, we entered into a securities purchase agreement with certain accredited investors (the “Investors”) and certain of our directors (the “Affiliates”), pursuant to which we issued (i) 631,282 shares
of our common stock to the Investors at a price of $8.95 per share, which represented a 15% discount to the volume weighted price of our common stock on April 8, 2021, and (ii) 560,461 shares of our common stock to the Affiliates at a price of
$11.33 per share, which amount equals the consolidated closing bid price of our common stock on April 9, 2021, for aggregate gross proceeds to us of $12,000,000 (the “PIPE Offering”).
In connection with the PIPE Offering, we agreed to use reasonable commercial efforts to file a Registration Statement on Form S-3 covering the resale of the shares of common stock sold in the PIPE Offering as soon as
practicable after the date on which we become eligible to use a Registration Statement on Form S-3.
The offer, sale and issuance of these securities were exempt from registration in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the
Securities Act and/or under Regulation D of the Securities Act, relative to transactions by an issuer not involving a public offering.
Item 3. |
Defaults Upon Senior Securities
|
None.
Item 4. |
Mine Safety Disclosures
|
Not applicable.
Item 5. |
Other Information
|
None.
Item 6. |
Exhibits
|
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Company’s Form S-4 (Reg. No. 333-250938) filed with the SEC on November 24, 2020, as
amended on December 31, 2020, January 19, 2021, February 1, 2021 and February 9, 2021).
|
|
Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Company’s Form S-4 (Reg. No. 333-250938) filed with the SEC on November 24, 2020, as amended on December 31,
2020, January 19, 2021, February 1, 2021 and February 9, 2021).
|
|
Form of Securities Purchase Agreement, dated April 12, 2021, by and between the Registrant and each of the investors and the affiliates (incorporated by reference to Exhibit 10.1 to the
Company’s Current Report on Form 8-K, filed with the SEC on April 13, 2021).
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document ).
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document.
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
|
101.CAL
|
Inline XBRL Taxonomy Calculation Linkbase Document.
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document.
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document.
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
* Filed herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 16, 2021.
FORIAN INC.
|
||
By:
|
/s/ Daniel Barton
|
|
Daniel Barton
|
||
Chief Executive Officer
|
||
(Principal Executive Officer)
|
||
By:
|
/s/ Clifford Farren
|
|
Clifford A. Farren
|
||
Chief Financial Officer
|
||
(Principal Financial Officer and Principal Accounting Officer)
|
45